Compare LARK & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LARK | TARA |
|---|---|---|
| Founded | 1885 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 167.8M | 165.5M |
| IPO Year | N/A | N/A |
| Metric | LARK | TARA |
|---|---|---|
| Price | $27.91 | $6.84 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $20.33 |
| AVG Volume (30 Days) | 8.4K | ★ 767.4K |
| Earning Date | 10-29-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.86% | N/A |
| EPS Growth | ★ 38.73 | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $64,367,999.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.83 | ★ N/A |
| Revenue Growth | ★ 12.95 | N/A |
| 52 Week Low | $20.99 | $2.77 |
| 52 Week High | $29.56 | $10.48 |
| Indicator | LARK | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 59.93 |
| Support Level | $27.26 | $6.21 |
| Resistance Level | $28.77 | $7.14 |
| Average True Range (ATR) | 0.92 | 0.64 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 39.57 | 66.31 |
Landmark Bancorp Inc is the bank holding company for Landmark National Bank, which is dedicated to providing quality financial and banking services. The Bank has continued to focus on increasing its originations of commercial, commercial real estate (CRE), and agricultural loans, which management believes will be more profitable and provide more growth for the Bank than traditional one-to-four-family residential real estate lending. In addition, it also invests in certain investment and mortgage-related securities using deposits and other borrowings as funding sources. Its primary deposit gathering and lending markets are geographically diversified with locations in central, eastern, southeast, and southwest Kansas.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).